by Stephen Manobiano | Jul 1, 2026 | business development, Founders and Business Leaders, Fractional, news
Ultra-sensitive multiplex immunoassay technology now detects low-abundance biomarkers in complex matrices like cerebrospinal fluid, enabling earlier-stage Alzheimer’s and neurodegenerative disease research that simply wasn’t possible a few years ago. p-Tau 217 went...
by Stephen Manobiano | Jul 1, 2026 | business development, Commercialization, CRM best practices, Data Management, Founders and Business Leaders, Fractional, Marketing, news, Sales
NGS isn’t “next gen” anymore. The core sequencing instrument market is dominated by a small number of established platform vendors, and that’s not changing. If your growth strategy still depends on competing for that instrument-level attention, you’re...
by Stephen Manobiano | Jul 1, 2026 | Automation, business development, Commercialization, CRM best practices, Data Management, Founders and Business Leaders, news, Sales
Labs are getting smaller, more automated, and more distributed. Instruments are shrinking and handling more of the manual work themselves. Research hubs outside the traditional life science centers are standing up modular, flexible labs instead of building large...
by Stephen Manobiano | Jul 1, 2026 | business development, Commercialization, Founders and Business Leaders, Fractional, Marketing, news, Sales
Biomarker-guided drug development is now structural, not a passing trend; pharma and biotech companies rely on PD biomarkers to select doses, prove mechanism of action, and stratify patients across oncology, immunology, neurology, and rare disease. If you provide...
by Stephen Manobiano | Jun 30, 2026 | Commercialization, Founders and Business Leaders, Fractional, Marketing, news, Sales
Genome editing is moving from a research tool into therapeutic development pipelines, and that shift is creating real, recurring demand for guide RNAs, delivery reagents, and validation kits. It’s also creating a commercial trap for reagent companies that don’t...